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Abstract: Hypertension is a major health problem worldwide and remains underdiagnosed and 
undertreated. Although public awareness and control of hypertension have improved over the 
last decade, only one-third of hypertensive patients achieve the rather conservative blood pres-
sure (BP) goal of ,140/90 mmHg. Most hypertensive patients require more than one drug for 
optimum BP control. Expert panels recommend use of combination therapy with two or more 
medications for Stage 2 and higher hypertension and in high-risk patients. However, the use 
of multiple drugs reduces patient compliance. Fixed-dose combination therapy helps improve 
patient compliance and thus achieve the target BP. Dose titration of the individual constituent 
drugs is recommended before switching to an equivalent fixed-dose combination. Random-
ized, controlled trials have shown that the fixed-dose combination of amlodipine–olmesartan 
medoxomil is more effective in lowering BP than monotherapy with either of these agents, 
with a similar side effect profile.
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Introduction
Uncontrolled hypertension is the leading risk factor for cardiovascular disease and 
mortality worldwide. In 2000, approximately one billion people worldwide had hyper-
tension, and this number is expected to increase by 60% to a total of 1.56 billion by 
2025.1 Hypertension affects approximately 30% of adults in the industrialized nations, 
and blood pressure (BP) reduction to the recommended levels of ,140/90 mmHg 
remains low at 32%. Even in patients with chronic kidney disease who have higher risk 
of cardiovascular disease and associated co-morbidities, only 36.8% achieve the BP 
target recommended by the Joint National Committee on Prevention, Evaluation, and 
Treatment of High BP (JNC-7). Effective BP control to ,140/90 mmHg reduces the 
incidence of heart failure by 50%, myocardial infarction by 25%, and stroke by 40%.2 
The continued poor rates of BP control indicate a persistent need for improved antihy-
pertensive therapy. Recent and ongoing clinical trials are utilizing combination therapy 
as initial treatment, especially in stage 2 hypertension (160 mmHg systolic or higher, 
diastolic 100 mmHg or higher), or higher degrees of hypertension, or if BP is > 20/10 
mmHg above the target. Combination therapy may potentially confer the advantage of 
improved efficacy through additive or synergistic effects. Rational add-on therapies to 
renin–angiotensin–aldosterone system inhibitors include thiazide diuretics (especially 
in hypertensive patients exhibiting a low-renin state, eg, Afro-Caribbean and black Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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Americans),3 aldosterone antagonists, and calcium channel 
blockers. Table 2 lists some of the benefits of the fixed-dose 
combinations of antihypertensive agents.
Advantages of combination therapy
Better blood pressure control
Initiating therapy with two agents is recommended for 
patients at high risk of a cardiovascular event or those with 
BP . 20/10 mmHg above goal (Table 1).4,5 A rational strat-
egy is to use agents with complementary mechanisms of 
action to enhance BP-lowering efficacy and prevent target 
organ damage. In experimental models, the combination 
of a calcium channel blocker with an agent that blocks 
angiotensin II improves endothelial function, inflammation, 
ventricular remodeling, and renal function to a greater degree 
than these drugs given as monotherapy.6 Several large ran-
domized trials have shown that monotherapy is ineffective in 
reducing BP to a predetermined target range. For instance, in 
the Antihypertensive and Lipid Lowering Treatment to Prevent 
Heart Attack (ALLHAT) trial, only 27% of 42,418 participants 
achieved the goal BP (,140/90 mmHg) on monotherapy, from 
a baseline mean systolic BP of 146 mmHg and 156 mmHg 
for previously treated and untreated patients, respectively.7 
In the Losartan Intervention For Endpoint (LIFE) trial, 90% 
of 9193 participants with hypertension and left ventricular 
hypertrophy required more than one antihypertensive agent 
to achieve a similar BP target (,140/90 mmHg) from a 
mean baseline of 174/97.8 mmHg.8 In the Avoiding Cardio-
vascular events through COMbination therapy in Patients 
LIving with Systolic Hypertension (ACCOMPLISH) trial, 
32.3% of participants treated with benazepril–amlodipine or 
benazepril–hydrochlorothiazide required additional antihy-
pertensive agents to reach the target BP of ,140/90 mmHg 
(,130/80 mmHg for patients with chronic kidney disease) 
from a baseline of 145/80 mmHg.9 In this randomized double-
blind trial, the target BP (,140/90 mmHg) was achieved in over 
78% of patients in the US cohort on the amlodipine–benazepril 
combination. In diabetics and in patients with chronic kidney 
disease the control rates were 72.5% and 70.8%, respectively. 
These results demonstrate that monotherapy is ineffective in 
achieving the target BP in the majority of hypertensive indi-
viduals. This is reflected in the recommendations by several 
advisory panels (Table 1). The JNC-7 guidelines recommend 
initiating therapy with two antihypertensive agents in patients 
with Stage 2 and higher levels of BP.4 The European Society 
of Hypertension also recommends initial combination anti-
hypertensive therapy in patients at high cardiovascular risk.10 
Calcium channel blockers and antagonists of angiotensin II are 
highly effective and widely used antihypertensive agents, and 
are being increasingly offered in fixed-dose combinations. In 
addition to lowering BP, these drugs have vasculoprotective 
and pleiotropic properties.11,12
Better compliance with  
antihypertensive therapy
Patient adherence to prescribed therapy and advice is a strong 
predictor of achieving BP control.13 The number of medications 
prescribed and the complexity of the treatment regimen are two 
important determinants of patient adherence.14 This has been 
shown in patients with a variety of different diseases. Adher-
ence improves with fewer medications or pills prescribed. 
Reducing the number of pills by using combinations of drugs 
reduces non-adherence compared with the same drugs given 
separately, even with the same frequency.15 A meta-analysis 
of nine studies comparing fixed-dose combinations versus 
the same drugs given separately for treatment of diabetes, 
hypertension, tuberculosis, and human immunodeficiency 
virus infection, reported that fixed-dose combinations reduce 
the rate of non-adherence by 26%.15 In this meta-analysis, a 
subgroup analysis of the four studies in hypertension showed 
that the fixed-dose combinations decreased the risk of medica-
tion non-adherence by 24% compared with free-drug combi-
nations. In a study of 198 hypertensive patients randomized 
to receive diltiazem twice daily or amlodipine once daily, the 
Table 1 Guidelines for initial combination therapy
Committee BP levels requiring initial combination  
therapy
JNC-735 Stage 2 ($160/100 mmHg) SBP . 20 mmHg  
or DBP . 10 mmHg above the goal
NKF36 SBP . 20 mmHg above the goal according to  
the stage of CKD and CvD risk
ADA37 BP . 130/80 mmHg and Type 2 diabetes
eSH10 High-risk patients according to total CvD risk
Abbreviations:  JNC-7,  Seventh  Report  of  the  Joint  National  Committee  on 
Prevention, Detection, evaluation, and Treatment of High Blood Pressure; SBP, 
systolic  blood  pressure;  DBP,  diastolic  blood  pressure;  NKF,  National  Kidney 
Foundation;  ADA,  American  Diabetes  Association;  eSH,  european  Society  of 
Hypertension; CKD, chronic kidney disease; CvD, cardiovascular disease; BP, blood 
pressure.
Table 2 Benefits of combination therapy in hypertension
•   Better adherence to therapy and simplification of the therapeutic regimen
• Better blood pressure control than monotherapy
•   Avoidance of dose-dependent adverse effects seen with higher doses 
of single agents
• Attenuation of the adverse effects of some agents when used alone
• Complementary/synergistic vasculoprotective or pleiotropic effects.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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patients on a once-daily regimen took their study drug on a 
regular schedule 86% ± 2% of times compared with 76% ± 2% 
for those who were on a twice-daily dosing schedule.16 In 
a retrospective analysis of data from a pharmacy claims 
database in the US,17 adherence to a fixed-dose combination 
of amlodipine–benazepril was compared with adherence to 
free-dose combination therapy of the two agents. Patients 
given two or more prescriptions for the fixed-dose combina-
tion (n = 2839) or the two components separately (n = 3367) 
were identified and followed up for an average of 259 days and 
247 days, respectively. Adherence to fixed-dose combination 
therapy (88%) was significantly greater than for free combina-
tion therapy (69%). The average annual cost of cardiovascular 
disease-related care per subject was also significantly lower in 
patients receiving the fixed-dose combination. Other studies 
have shown that adherence in hypertensive patients is inversely 
related to the BP control achieved.13
Fixed-dose combination  
of amlodipine–olmesartan 
medoxomil
The antagonists of angiotensin II have favorable metabolic, 
renal, cardiovascular, and quality of life effects compared 
with other antihypertensive agents. A post hoc analysis 
of the ACCOMPLISH trial reported that initial treatment 
with benazepril plus amlodipine slowed the progression of 
nephropathy to a greater extent than benazepril plus hydro-
chlorothiazide. Currently, the angiotensin II blockers are 
recommended as first-line drugs in patients with diabetes, 
proteinuria, and systolic heart failure. These drugs reduce 
BP and proteinuria, and slow the progression of diabetic 
nephropathy.18 In patients with Type 2 diabetes and overt 
nephropathy, the renoprotective action of angiotensin recep-
tor blockers was evident in two large-scale trials. RENAAL 
(Reduction of Endpoints in non-insulin dependent diabetes 
mellitus [NIDDM] with the Angiotensin II Antagonist Losar-
tan Study)19 demonstrated a 16% risk reduction in the primary 
composite endpoint of doubling of baseline serum creatinine, 
end-stage renal disease, or death from a cardiovascular cause, 
with losartan compared with placebo. The Irbesartan Diabetic 
Nephropathy Trial (IDNT)20 demonstrated superiority of irbe-
sartan compared with amlodipine and conventional therapy in 
prevention of doubling of baseline serum creatinine, develop-
ment of end-stage renal disease, or all-cause mortality, with 
similar BP reduction across all three cohorts.
Calcium channel blockers are effective in lowering BP 
and among the most commonly used antihypertensive drugs. 
Therefore, the angiotensin II antagonists are increasingly 
being used with calcium channel blockers as a fixed-dose 
combination. The fixed-dose combination of olmesartan–
amlodipine is the focus of this review. A brief discussion of 
the individual components will be followed by a discussion 
of the efficacy and tolerability of the fixed-dose combination 
of these agents.
Amlodipine
Amlodipine is a third-generation dihydropyridine calcium 
channel blocker and is the most commonly used agent in its 
class. More than 90% of amlodipine is absorbed and 95% 
of circulating amlodipine is bound to plasma proteins. Due 
to lack of significant first-pass hepatic metabolism, it has a 
prolonged duration of action, with a half-life of 35–45 hours. 
Like other calcium channel blockers, it acts by decreasing 
Ca2+ entry to cells through L-type Ca2+ channels, resulting 
in vascular smooth muscle relaxation. Its action peaks at 
10–14 hours and steady-state plasma levels are reached in 
7–8 days. About 90% of amlodipine is converted to inactive 
metabolites via hepatic metabolism, and 60% of the metabo-
lites are excreted in the urine. In patients with kidney disease, 
the pharmacokinetics of amlodipine are minimally changed. 
Dose adjustment may be needed in hepatic disease. Another 
property unique to amlodipine (with the possible exception 
of azelnidipine, not available in the US) is its antioxidant 
activity. Amlodipine is superior to felodipine, diltiazem, 
verapamil, and captopril at pharmacologically relevant 
doses in inhibiting lipid peroxidation in isolated membrane 
vesicles enriched with polyunsaturated fatty acids.21 This 
antioxidant property of amlodipine is independent of calcium 
channel blockade and is related to its chemical structure and 
direct physicochemical interactions with the membrane lipid 
bilayer. Due to its high lipophilicity, amlodipine is highly 
concentrated in the cell membrane, which enables it to scav-
enge free radicals effectively and break the lipid peroxidation 
chain reaction. Two abstractable hydrogen atoms associ-
ated with its aromatic rings further enhance its antioxidant 
activity.22 There is also evidence that amlodipine modulates 
the activity of PKC-α, a powerful activator of nicotinamide 
adenine dinucleotide phosphate oxidase.
Amlodipine is very effective in lowering BP and reduces 
cardiovascular disease morbidity and mortality. This was 
shown in ALLHAT,23 which randomized 42,418 high-risk 
patients to receive chlorthalidone, amlodipine, lisinopril, or 
doxazosin. The study participants were .55 years of age, had 
Stage 1 or 2 hypertension with one additional cardiovascu-
lar disease risk factor, and 36% had diabetes. In this study, 
amlodipine was as effective as chlorthalidone in reducing the Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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primary combined endpoint of fatal coronary heart disease or 
nonfatal myocardial infarction (relative risk, 0.98; 95% confi-
dence interval 0.90–1.07). Its efficacy in reducing combined 
coronary heart disease events and end-stage renal disease 
was comparable with that of chlorthalidone. However, the 
incidence of heart failure was 38% higher in patients assigned 
to amlodipine than in those assigned to chlorthalidone in 
the absence of concomitant angiotensin II inhibitor therapy 
in either group. The incidence of other adverse effects was 
similar in both groups. In the Valsartan Antihypertensive 
Long-Term Use Evaluation (VALUE) trial,24 amlodipine 
was more effective than valsartan in reducing the prespeci-
fied secondary endpoint of fatal and nonfatal myocardial 
infarction (4.1% versus 4.8%, P = 0.02). Overall, there were 
no differences in the primary composite endpoint of the 
time to first cardiac event. In this study systolic BP control 
(,140/90 mmHg) was achieved in 4392 (58%) of patients on 
valsartan and 4793 (64%) of those on amlodipine. Diastolic 
BP (,90 mmHg) control was achieved in 6652 (88%) and 
6940 (92%) for valsartan and amlodipine, respectively. The 
target BP (,140 mmHg systolic and ,90 mmHg diastolic) 
was achieved in 4274 (56%) patients in the valsartan group 
and 4694 (62%) in the amlodipine group. The baseline BP 
in both groups was 154/88 mmHg. Both treatments were 
well tolerated. The incidence of edema was twice as high in 
amlodipine-treated patients (32.9%) as in valsartan-treated 
patients (14.9%), and hypokalemia was seen in the 6.1% 
of the patients treated with amlodipine versus 3.2% in the 
valsartan-treated group. A later substudy analysis of 7080 
participants, analyzed according to whether they were still 
on monotherapy at the end of the first six months, showed 
that amlodipine increased the risk of congestive heart failure 
by 22%,25 although the original analysis had shown no dif-
ference. Both of these large randomized trials suggested a 
higher risk of new onset congestive heart failure with amlo-
dipine monotherapy. However, in patients with pre-existing 
congestive heart failure, addition of amlodipine does not 
increase mortality or morbidity.26 Furthermore, the increased 
risk of congestive heart failure seen with amlodipine mono-
therapy may be neutralized when it is combined with an 
angiotensin II antagonist.27
Olmesartan medoxomil
Olmesartan medoxomil, a prodrug hydrolyzed to olmesar-
tan during absorption from the gastrointestinal tract, is a 
specific angiotensin II Type I receptor (AT-R1) antagonist. 
Olmesartan medoxomil has 12,500-fold greater affinity 
for the AT1 receptor than for the AT2 receptor. Olmesartan 
medoxomil has doses ranging from 2.5 mg to 40 mg. The 
duration of inhibitory effect is related to the dose, with doses 
of olmesartan medoxomil .40 mg giving .90% inhibi-
tion at 24 hours. The absolute bioavailability of olmesartan 
medoxomil is approximately 26%, and its antihypertensive 
effect is achieved within 1–2 hours, with maximal reduction 
of BP achieved within 4–6 hours. The volume of distribution 
of olmesartan medoxomil is approximately 17 L. Olmesartan 
medoxomil is highly bound to plasma proteins (99%) and 
does not cross into red blood cells. It crosses the blood–brain 
barrier in rats poorly, but does cross the placental barrier 
and is distributed to the fetus. Olmesartan medoxomil is 
also distributed to milk at low levels in rats. Following the 
rapid and complete conversion of olmesartan medoxomil to 
olmesartan during absorption, no further metabolism takes 
place. Approximately 35%–50% gets excreted in the urine 
unchanged, while the remainder is eliminated in feces via 
the bile. Olmesartan medoxomil, like other angiotensin II 
antagonists, also exerts significant BP-independent beneficial 
effects. It reduces the expression of nicotinamide adenine 
dinucleotide phosphate oxidase subunits, the major source 
of free oxygen radicals in blood vessels.
Olmesartan medoxomil–amlodipine 
combination therapy
The efficacy and safety of olmesartan medoxomil–amlodipine 
combination therapy in the treatment of hypertension has 
been reported in several randomized controlled trials. In one 
trial,281017 patients with a baseline BP of 164/102 mmHg 
were given open-label amlodipine 5 mg daily as mono-
therapy. After eight weeks, the non-responders (n = 755) 
were randomized to receive placebo plus amlodipine 5 mg 
or a combination of olmesartan medoxomil (10–40 mg) 
with amlodipine 5 mg for eight weeks. At week 16, patients 
who had achieved diastolic BP , 90 mmHg and/or systolic 
BP , 140 mmHg continued on randomized treatment for a 
further eight weeks. Patients with both systolic BP and dia-
stolic BP $ 140/90 mmHg at week 16 had their medication 
uptitrated to olmesartan medoxomil–amlodipine 20/5 mg, 
olmesartan medoxomil–amlodipine 40/5 mg, or olmesartan 
medoxomil–amlodipine 40/10 mg. The combination of 
olmesartan medoxomil 10–40 mg with amlodipine 5 mg 
for eight weeks reduced mean systolic BP/diastolic BP by 
up to 16.8 mmHg and 9.6 mmHg, respectively. The addi-
tional adjusted mean change in seated diastolic BP (primary 
endpoint) with last observation carried forward compared 
with placebo–amlodipine 5 mg was -2.0 mmHg (P = 0.02), 
-3.7 mmHg (P , 0.0001), and -3.8 mmHg (P , 0.0001) Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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for olmesartan medoxomil–amlodipine 10/5 mg, 20/5 mg, 
and 40/5 mg, respectively.
In another randomized, double-blind, parallel-group, 
multicenter trial,29 538 patients with moderate-to-severe 
hypertension (systolic BP/diastolic BP $ 160/100 mmHg) 
were given open-label olmesartan medoxomil 20 mg daily 
for eight weeks. At the end of eight weeks, patients whose 
BP was still above target (nondiabetics with systolic BP/
diastolic BP $ 140/90 mmHg and diabetics with systolic 
BP/diastolic BP $ 130/80 mmHg) were assigned to amlo-
dipine 5 or 10 mg/day or a placebo in addition to olmesartan 
medoxomil, in a double-blind design. After eight weeks 
(with last observation carried forward), the adjusted mean 
change in seated diastolic BP from baseline was -7.6 mmHg 
for olmesartan medoxomil–placebo, -10.4 mmHg for 
olmesartan medoxomil–amlodipine 20/5 mg (P = 0.0006) 
and -10.9 mmHg for olmesartan medoxomil–amlodipine 
20/10 mg (P , 0.0001). Mean changes in seated systolic 
BP from baseline with olmesartan medoxomil–amlodipine 
20/5 mg and olmesartan medoxomil–amlodipine 20/10 mg 
were -16.1 and -16.7 mmHg, respectively (P , 0.0001). 
Achievement of BP goal rates was significantly higher with 
olmesartan medoxomil–amlodipine 20/5 mg and olmesar-
tan medoxomil–amlodipine 20/10 mg (44.5% and 45.8%, 
respectively; P = 0.0011 and P = 0.0004) versus olmesartan 
medoxomil–placebo (28.5%). The incidence of drug-related 
adverse events was 8.9% for olmesartan medoxomil–placebo, 
7.7% for olmesartan medoxomil–amlodipine 20/5 mg, and 
11.3% for olmesartan medoxomil–amlodipine 20/10 mg 
(P = 0.490).
Chrysant et al30 randomized 1940 patients according to 
a double-blind, placebo-controlled, factorial design in the 
COACH (The Combination of Olmesartan medoxomil and 
Amlodipine besylate in Controlling High blood pressure) 
trial. Mean age of the study population was 54.0 years, 54.3% 
were men, and 19.8% were aged . 65 years. The mean base-
line BP was 164/102 mmHg, and 79.3% of patients had Stage 
2 hypertension. Patients were randomized to receive either an 
olmesartan medoxomil–amlodipine combination, olmesartan 
medoxomil alone, or amlodipine alone. The combination of 
olmesartan medoxomil–amlodipine caused dose-dependent 
reductions in seated systolic BP (from -13.8 mmHg with 
olmesartan medoxomil–amlodipine 10/5 mg to -19.0 mmHg 
with olmesartan medoxomil–amlodipine 40/10 mg) and 
seated systolic BP (from -23.6 mmHg with olmesartan 
medoxomil–amlodipine 20/5 mg to -30.1 mmHg with 
olmesartan medoxomil–amlodipine 40/10 mg) that were sig-
nificantly greater than the reductions with the   corresponding 
component monotherapies (P , 0.001). The number of 
patients achieving the BP goal ranged from 57/163 (35.0%) 
to 84/158 (53.2%) in the combination therapy group, from 
32/160 (20.0%) to 58/160 (36.3%) in the olmesartan medox-
omil monotherapy group, and from 34/161 (21.1%) to 53/163 
(32.5%) in the amlodipine monotherapy group (P , 0.005, 
combination therapy versus component monotherapies), 
compared with 14/160 (8.8%) in the placebo group. The 
results of this study are summarized in Table 3. The most 
common adverse events were edema (ranging from 9.9% 
for olmesartan medoxomil 20 mg to 36.8% for amlodipine 
10 mg, compared with 12.3% for placebo) and headache 
(ranging from 2.5% for olmesartan medoxomil–amlodipine 
10/5 mg to 8.7% for olmesartan medoxomil 20 mg, compared 
with 14.2% for placebo). These studies show that a fixed-
dose combination of olmesartan medoxomil–amlodipine is 
effective and well tolerated, with an adverse effect profile 
similar to those of the individual drugs. Studies in special 
patient populations also confirm the efficacy and tolerability 
of this combination.
Olmesartan medoxomil–amlodipine 
in specific populations
A recently published COACH sub-study evaluated the long-
term efficacy of the combination of amlodipine and olm-
esartan medoxomil with or without hydrochlorothiazide.31 
The following findings were reported from this study and 
the subgroup analyses.
elderly patients
Mean seated BP reductions for patients aged , and $ 65 
years at week 52 were 31.0/19.2 mmHg and 38.3/21.5 mmHg, 
respectively. Baseline seated BP and reduction in seated BP 
reductions were greater in patients eventually titrated to 
amlodipine–olmesartan–hydrochlorothiazide 10/40/25 mg 
per day. In general, the addition of hydrochlorothiazide 
caused greater seated BP reduction in patients aged $ 65 
years. Patients aged $ 65 years had greater reductions in 
seated systolic BP at each titration step, compared with 
patients aged , 65 years.
Black patients
Mean seated BP reduction at week 52 for black and non-
black patients was 30.8/18.7 mmHg and 33.0/20.0 mmHg, 
respectively. Once again, baseline seated BP was highest 
and seated systolic BP reduction greatest in patients titrated 
to amlodipine–olmesartan medoxomil–hydrochlorothiazide 
10/40/25 mg per day. Approximately 20% of black patients Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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remained on the initial dose of amlodipine–olmesartan 
medoxomil 5/40 mg per day, compared with 34.9% of 
nonblacks. More black patients required titration to higher 
doses than nonblacks. Among black patients, 35.9% 
were uptitrated to amlodipine–olmesartan medoxomil–
hydrochlorothiazide 10/40/25 mg per day, and 49.7% 
on this dose achieved their seated BP goal at week 52. 
Among black patients, the greatest seated BP reduction was 
observed in patients switching from amlodipine–olmesartan 
medoxomil–hydrochlorothiazide 10/40/12.5 mg per day to 
amlodipine–olmesartan medoxomil–hydrochlorothiazide 
10/40/25 mg per day.
Patients with diabetes
At week 52, seated BP reduction from baseline in patients 
with diabetes was 34.2/19.9 mmHg compared with 
32.1/19.6 mmHg in patients without diabetes. Only 26.9% 
of patients with diabetes achieved the seated BP goal of 
,130/80 mmHg, whereas 72.9% of patients without diabetes 
achieved their seated BP goal of ,140/90 mmHg with the ini-
tial dose of amlodipine–olmesartan medoxomil 5/40 mg per 
day. By week 52, 48.0% of patients with diabetes were titrated 
to amlodipine–olmesartan medoxomil–hydrochlorothiazide 
10/40/25 mg per day, and 21.1% achieved the seated BP goal 
of ,130/80 mmHg.
In summary, the overall percentage of patients achieving 
their BP goal at week 52 on the combination of amlodipine-
olmesartan medoxomil was 61.0% for patients aged $ 65 
years, 68.1% for patients aged , 65 years, 63.3% for blacks, 
67.8% for nonblacks, 26.9% for patients with diabetes, and 
72.9% of patients without diabetes. However, the study was 
not powered to show statistically significant differences 
between subgroups. Combination therapy was well toler-
ated, and no safety issues were noted. The most common 
adverse events were edema (ranging from 9.9% with olm-
esartan medoxomil 20 mg to 36.8% with amlodipine 10 mg, 
compared with 12.3% with placebo) and headache (ranging 
from 2.5% with olmesartan medoxomil–amlodipine 10/5 mg 
to 8.7% with olmesartan medoxomil 20 mg, compared 
with 14.2% for placebo). Specifically, drug-related edema 
occurred in 7.0%, 11.1%, 9.1%, and 10.7% of patients 
receiving amlodipine–olmesartan medoxomil 5/40 mg per 
day, amlodipine–olmesartan medoxomil 10/40 mg per day, 
amlodipine–olmesartan medoxomil–hydrochlorothiazide 
10/40/12.5 mg per day, and amlodipine–olmesartan 
medoxomil–hydrochlorothiazide 10/40/25 mg per day, 
respectively.
Another study32 in 692 patients reported that co- 
administration of olmesartan medoxomil and amlodipine 
with a thiazide diuretic was better in achieving target BP, 
especially when a higher dose of the diuretic was used. Patients 
with moderate-to-severe hypertension who were inadequately 
controlled (BP . 140/90 mmHg) with amlodipine 5 mg/day 
monotherapy and who subsequently completed 16 weeks 
of double-blind combination treatment with olmesartan 
medoxomil–  amlodipine entered a 28-week open-label phase 
in which all patients initially received olmesartan medoxomil–
amlodipine 40/5 mg/daily. After four, 10, and 19 weeks, patients 
with inadequate BP control had their doses increased in a step-
wise manner to olmesartan medoxomil–amlodipine 40/10 mg, 
olmesartan medoxomil–amlodipine–hydrochlorothiazide 
40/10/12.5 mg, and olmesartan medoxomil–amlodipine–
hydrochlorothiazide 40/10/25 mg. Overall, 66.9% of patients 
achieved the target BP systolic BP , 140 mmHg and diastolic 
BP , 90 mmHg for patients without diabetes, and systolic 
BP , 130 mmHg and diastolic BP , 80 mmHg for patients 
with diabetes.
Daiichi Sankyo, Inc. markets the combination of 
amlodipine–olmesartan medoxomil as AZOR®. The different 
dose combinations of amlodipine–olmesartan medoxomil 
available in the US and Europe are 5/20, 10/20, 5/40, and 
10/40 mg. Although monotherapy can be directly switched 
to fixed-dose combination, it is recommended to titrate the 
individual components separately until a suitable dose of each 
drug is established before switching to the fixed-dose combi-
nation. Caution and close monitoring of potassium and creati-
nine is needed while titrating angiotensin-converting enzyme 
inhibitors and angiotensin receptor blockers   containing 
Table 3 Proportion of patients achieving target blood pressure (,140/90 mmHg or ,130/80 mmHg in patients with diabetes mellitus) 
by week eight/last observation carried forward according to subgroup and treatment regimen
Goal BP achieved (%) Age Race Diabetes status BMI
,65 $65 Black Nonblack DM non-DM ,30 kg/m2 $30 kg/m2
Placebo 10.9 0 4.4 10.4 8.7 8.8 12.0 7.3
Amlodipine 10 mg 32.8 31.1 43.6 29.0 8.7 36.4 30.3 34.4
Olmesartan 40 mg 41.1 16.1 15.9 44.0 9.5 40.3 47.9 30.0
Amlodipine–olmesartan (10/40 mg) 56.3 21.2 38.2 52.0 12.5 55.5 53.3 46.0
Abbreviations: DM, diabetes mellitus; BMI, body mass index; BP, blood pressure.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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fixed-dose combinations. Dosage may be increased after two 
weeks, and a smaller dose combination should be chosen for 
elderly patients (.65 years) and patients with chronic kidney 
disease. No specific data exist on drug interactions of this 
fixed-dose combination, and the guidelines for the individual 
components should be followed.
Peripheral edema was found to be significantly less com-
mon for olmesartan medoxomil–amlodipine 40/10 mg per 
day than for amlodipine monotherapy 10 mg/day.28
A controversial effect of olmesartan medoxomil is that it 
improves myocardial function independent of BP reduction in 
hypertensive patients. Attenuation of inflammatory changes 
and myocardial hypertrophy may play an important role.33 
Rosendorff et al34 randomized 102 patients with hyperten-
sion, left ventricular hypertrophy, and vascular hypertrophy to 
either amlodipine or olmesartan for 52 weeks in a Phase IIIb 
study. Add-on hydrochlorothiazide and terazosin were 
allowed if needed to achieve the target BP (,140/90 mmHg 
for non-diabetics and ,135/85 mmHg for diabetics). At the 
end of 52 weeks, there were no significant changes in left 
ventricular compliance or carotid or femoral artery wall-to-
lumen ratios in either treatment group.
Summary
Hypertension is the leading cause of cardiovascular disease 
morbidity and mortality. Despite the availability of many 
effective antihypertensive agents, only 37% of the hyper-
tensive patients achieve their target BP. Most patients with 
Stage 2 or higher hypertension and those with a high risk of 
cardiovascular disease require more than one agent to control 
their BP. Experts recommend initiating antihypertensive 
therapy using a combination of agents with complementary 
mechanisms of action in these patients. In long-term treat-
ment of hypertension, single-pill combinations are associated 
with better drug adherence and better outcomes in compari-
son with free drug combinations.
Several randomized studies have demonstrated the 
superiority of using combination drug therapy, especially 
calcium channel blockers and the angiotensin II antagonists, 
in achieving target BP in various subgroups, while minimiz-
ing the incidence of adverse events seen with the treatment of 
hypertension using higher doses of a single agent. Addition of 
a thiazide diuretic to a calcium channel blocker, and a renin 
angiotensin aldosterone system antagonist combination fur-
ther potentiates the antihypertensive effects of these drugs.
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